Hans L Rieder
Overview
Explore the profile of Hans L Rieder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Chiang C, Lin C, Chien S, Wang C, Huang Y, Huang W, et al.
J Microbiol Immunol Infect
. 2023 Oct;
56(6):1245-1252.
PMID: 37802687
Background: Presumptive tuberculosis (TB) cases commonly had two to three sputum examinations in Taiwan. The incremental yield of serial sputum examinations has not been assessed before. Methods: In a pragmatic...
3.
4.
5.
Raviglione M, Rieder H
J Clin Tuberc Other Mycobact Dis
. 2021 Jul;
24:100251.
PMID: 34195387
No abstract available.
6.
7.
8.
Chiang C, Trebucq A, Piubello A, Rieder H, Schwoebel V, Van Deun A
Eur Respir J
. 2020 Jun;
55(6).
PMID: 32499309
No abstract available.
9.
Van Deun A, Decroo T, Maug A, Hossain M, Gumusboga M, Mulders W, et al.
PLoS One
. 2020 May;
15(5):e0233500.
PMID: 32421749
Background: Meta-analyses on impact of isoniazid-resistant tuberculosis informed the World Health Organization recommendation of a levofloxacin-strengthened rifampicin-based regimen. We estimated the effect of initial rifampicin resistance (Rr) and/or isoniazid resistance...
10.
Schwoebel V, Trebucq A, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, et al.
EClinicalMedicine
. 2020 Apr;
20:100268.
PMID: 32300732
Background: Treatment outcomes of the shorter regimen for rifampicin-resistant tuberculosis are not completely established. We report on these outcomes two years after treatment completion among patients enrolled in an observational...